NEW YORK ─ iAssay said on Wednesday that its point-of-care, portable testing reader model 2030 is being used in field studies by a FIND-led consortium developing a test to detect Buruli ulcer, a debilitating disease caused by the bacterium Mycobacterium ulcerans that starts as an inconspicuous papule and degenerates into large open wounds if left untreated.
To develop the test, Geneva-based FIND is leading a consortium involving Nagasaki University, the Swiss Tropical and Public Health Institute in Bern, Switzerland; and Drugs & Diagnostics for Tropical Diseases in San Diego.
Global Health Technology Innovation Fund, the Medicor Foundation, and the Anesvad Foundation are providing funding for its development.
The rapid lateral flow assay uses magnetic nanoparticles and antibodies to concentrate and detect a biomarker of the disease. A first-generation prototype is being evaluated at the Buruli Ulcer Laboratory Network, Centre Pasteur du Cameroun, in Yaoundé, Cameroon, and the Hope Commission and Centre Pasteur in Abidjan, Ivory Coast.
iAssay said its reader model is being used in the field to quantify test results by measuring the intensity of the test and control lines.